Skip to main content

Advertisement

SpringerLink
Log in

Characterization of M1/M2 Tumour-Associated Macrophages (TAMs) and Th1/Th2 Cytokine Profiles in Patients with NSCLC

  • Original Article
  • Published:
Cancer Microenvironment

Abstract

Lung cancer is one of the most commonly reported cancers, and is known to be associated with a poor prognosis. The function of tumour-associated macrophages (TAMs) in lung cancer patients is multifaceted and the literature shows conflicting roles. (I) To analyze the Th1 and Th2 cytokine levels that contribute to the differentiation of M1 and M2 macrophage populations in the serum of patients with NSCLC versus non-cancer controls; and (II) To characterize the M1 and M2 macrophage populations within TAMs in different subtypes of NSCLC compared to non-tumour tissue. The Th1 and Th2 cytokine levels were analyzed in serum using the Bio-Plex assay. In addition, TAMs subsets from non-tumour and tumour tissues were analyzed using immunohistochemistry (IHC). The level of IL-1β, IL-4, IL-6 and IL-8 was found to be increased in the serum of patients with large cell carcinoma but not in other NSCLC subtypes compared to non-cancer controls. In addition, the expression of CD68 and M2 marker CD163 was found to be increased (P ≤ 0.0001) in all NSCLC subtypes compared to non-tumour tissues. In contrast, the expression of iNOS (M1 marker) was decreased in the tumour tissue of patients with adenocarcinoma (P ≤ 0.01) and squamous carcinoma (P ≤ 0.05) but not in large cell carcinoma compared to non-tumour tissue. The results of this study indicate that NSCLC might have the ability to alter phenotype within the lung tumour areas in the local environment (TAMs) but not in the bloodstream in the systemic environment (serum) except for large cell carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Shih J-Y, Yuan A, Chen JJ-W, Yang P-C (2006) Tumor-associated macrophage: its role in cancer invasion and metastasis. J Cancer Mol 2(3):101–106

    CAS  Google Scholar 

  2. Lewis CE, Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66(2):605–612. doi:10.1158/0008-5472.CAN-05-4005

    Article  CAS  PubMed  Google Scholar 

  3. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23(11):549–555

    Article  CAS  PubMed  Google Scholar 

  4. Dirkx AE, Oude Egbrink MG, Wagstaff J, Griffioen AW (2006) Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol 80(6):1183–1196, 10.1189/jlb.0905495

    Article  CAS  PubMed  Google Scholar 

  5. Lamagna C, Aurrand-Lions M, Imhof BA (2006) Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol 80(4):705–713. doi:10.1189/jlb.1105656

    Article  CAS  PubMed  Google Scholar 

  6. Quatromoni JG, Eruslanov E (2012) Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res 4(4):376–389

    PubMed  PubMed Central  Google Scholar 

  7. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25(12):677–686

    Article  CAS  PubMed  Google Scholar 

  8. Lopez-Gonzalez JS, Avila-Moreno F, Prado-Garcia H, Aguilar-Cazares D, Mandoki JJ, Meneses-Flores M (2007) Lung carcinomas decrease the number of monocytes/macrophages (CD14+ cells) that produce TNF-[alpha]. Clin Immunol 122(3):323–329

    Article  CAS  PubMed  Google Scholar 

  9. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P (2009) Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J 33(1):118–126. doi:10.1183/09031936.00065708

    Article  CAS  PubMed  Google Scholar 

  10. Redente EF, Dwyer-Nield LD, Merrick DT, Raina K, Agarwal R, Pao W, Rice PL, Shroyer KR, Malkinson AM (2010) Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization. Am J Pathol 176(6):2972–2985. doi:10.2353/ajpath.2010.090879

    Article  PubMed  PubMed Central  Google Scholar 

  11. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O’Neill A, Mier J, Ochoa AC (2005) Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65(8):3044–3048

    CAS  PubMed  Google Scholar 

  12. Chang CI, Liao JC, Kuo L (2001) Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res 61(3):1100–1106

    CAS  PubMed  Google Scholar 

  13. Biswas SK, Sica A, Lewis CE (2008) Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 180(4):2011–2017

    Article  CAS  PubMed  Google Scholar 

  14. Gorrin-Rivas MJ, Arii S, Mori A, Takeda Y, Mizumoto M, Furutani M, Imamura M (2000) Implications of human macrophage metalloelastase and vascular endothelial growth factor gene expression in angiogenesis of hepatocellular carcinoma. Ann Surg 231(1):67–73

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Edin S, Wikberg ML, Dahlin AM, Rutegard J, Oberg A, Oldenborg PA, Palmqvist R (2012) The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One 7(10), e47045. doi:10.1371/journal.pone.0047045

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Edin S, Wikberg ML, Oldenborg PA, Palmqvist R (2013) Macrophages: good guys in colorectal cancer. OncoImmunology 2(2), e23038. doi:10.4161/onci.23038

    Article  PubMed  PubMed Central  Google Scholar 

  17. Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122(3):787–795. doi:10.1172/jci59643

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. UyBico SJ, Wu CC, Suh RD, Le NH, Brown K, Krishnam MS (2010) Lung cancer staging essentials: the new TNM staging system and potential imaging pitfalls. Radiographics 30(5):1163–1181. doi:10.1148/rg.305095166

    Article  PubMed  Google Scholar 

  19. Welsh TJ, Green RH, Richardson D, Waller DA, O’Byrne KJ, Bradding P (2005) Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 23(35):8959–8967. doi:10.1200/jco.2005.01.4910

    Article  Google Scholar 

  20. Wang R, Zhang J, Chen S, Lu M, Luo X, Yao S, Liu S, Qin Y, Chen H (2011) Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. Lung Cancer (Amsterdam, Netherlands) 74(2):188–196. doi:10.1016/j.lungcan.2011.04.009

    Article  Google Scholar 

  21. Takanami I, Takeuchi K, Kodaira S (1999) Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology 57(2):138–142

    Article  CAS  PubMed  Google Scholar 

  22. Ohtaki Y, Ishii G, Nagai K, Ashimine S, Kuwata T, Hishida T, Nishimura M, Yoshida J, Takeyoshi I, Ochiai A (2010) Stromal macrophage expressing CD204 is associated with tumor aggressiveness in lung adenocarcinoma. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 5(10):1507–1515. doi:10.1097/JTO.0b013e3181eba692

    Google Scholar 

  23. Zeni E, Mazzetti L, Miotto D, Lo Cascio N, Maestrelli P, Querzoli P, Pedriali M, De Rosa E, Fabbri LM, Mapp CE, Boschetto P (2007) Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J 30(4):627–632. doi:10.1183/09031936.00129306

    Article  CAS  PubMed  Google Scholar 

  24. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P (2011) The tissue microlocalisation and cellular expression of CD163, VEGF, HLA-DR, iNOS, and MRP 8/14 is correlated to clinical outcome in NSCLC. PLoS One 6(7), e21874. doi:10.1371/journal.pone.0021874

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Bingle L, Brown N, Lewis C (2002) The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196(3):254–265

    Article  CAS  PubMed  Google Scholar 

  26. Toomey D, Smyth G, Condron C, Kelly J, Byrne AM, Kay E, Conroy RM, Broe P, Bouchier-Hayes D (2003) Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: No association with prognosis identified in 3-year follow-up. Int J Cancer J Int Cancer 103(3):408–412. doi:10.1002/ijc.10836

    Article  CAS  Google Scholar 

  27. Tataroglu C, Kargi A, Ozkal S, Esrefoglu N, Akkoclu A (2004) Association of macrophages, mast cells and eosinophil leukocytes with angiogenesis and tumor stage in non-small cell lung carcinomas (NSCLC). Lung Cancer (Amsterdam, Netherlands) 43(1):47–54

    Article  Google Scholar 

  28. Ma J, Liu L, Che G, Yu N, Dai F, You Z (2010) The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 10:112. doi:10.1186/1471-2407-10-112

    Article  PubMed  PubMed Central  Google Scholar 

  29. Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, Vago L, Nebuloni M, Mantovani A, Sica A (2006) A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 107(5):2112–2122. doi:10.1182/blood-2005-01-0428

    Article  CAS  PubMed  Google Scholar 

  30. Dinapoli MR, Calderon CL, Lopez DM (1996) The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduce expression of the inducible nitric oxide synthase gene. J Exp Med 183(4):1323–1329

    Article  CAS  PubMed  Google Scholar 

  31. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 26(21):3543–3551. doi:10.1200/jco.2007.15.0375

    Article  CAS  Google Scholar 

  32. Zhang B, Yao G, Zhang Y, Gao J, Yang B, Rao Z, Gao J (2011) M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma. Clinics 66(11):1879–1886. doi:10.1590/S1807-59322011001100006

    Article  PubMed  PubMed Central  Google Scholar 

  33. Chung FT, Lee KY, Wang CW, Heh CC, Chan YF, Chen HW, Kuo CH, Feng PH, Lin TY, Wang CH, Chou CL, Chen HC, Lin SM, Kuo HP (2012) Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. Int J Cancer J Int Cancer 131(3):E227–E235. doi:10.1002/ijc.27403

    Article  CAS  Google Scholar 

  34. Belardelli F, Ferrantini M (2002) Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol 23(4):201–208

    Article  CAS  PubMed  Google Scholar 

  35. Matanic D, Beg-Zec Z, Stojanovic D, Matakoric N, Flego V, Milevoj-Ribic F (2003) Cytokines in patients with lung cancer. Scand J Immunol 57(2):173–178

    Article  CAS  PubMed  Google Scholar 

  36. Romagnani S (1995) Biology of human TH1 and TH2 cells. J Clin Immunol 15(3):121–129

    Article  CAS  PubMed  Google Scholar 

  37. Romagnani S (1996) Th1 and Th2 in human diseases. Clin Immunol Immunopathol 80(3 Pt 1):225–235

    Article  CAS  PubMed  Google Scholar 

  38. Gursel G, Gokcora N, Elbeg S, Samurkasoglu B, Ekim N (1995) Tumor necrosis factor-alpha (TNF-alpha) in pleural fluids. Tuber Lung Dis 76(4):370–371

    Article  CAS  PubMed  Google Scholar 

  39. Brooks N, Stojanovska L, Grant P, Apostolopoulos V, McDonald CF, Pouniotis DS (2012) Characterization of blood monocyte phenotype in patients with endometrial cancer. Int J Gynecol Cancer 22(9):1500–1508. doi:10.1097/IGC.0b013e3182249273

    PubMed  Google Scholar 

  40. Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M (2010) Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell 17(1):89–97. doi:10.1016/j.ccr.2009.12.008

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Yi H, Cho HJ, Cho SM, Jo K, Park JA, Kim NH, Amidon GL, Kim JS, Shin HC (2012) Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells. Int J Oncol 41(1):310–316. doi:10.3892/ijo.2012.1447

    CAS  PubMed  Google Scholar 

  42. De Vita F, Orditura M, Auriemma A, Infusino S, Roscigno A, Catalano G (1998) Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 5(3):649–652

    PubMed  Google Scholar 

  43. Crohns M, Saarelainen S, Laine S, Poussa T, Alho H, Kellokumpu-Lehtinen P (2010) Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy—association of interleukin-8 and VEGF with survival. Cytokine 50(1):30–36. doi:10.1016/j.cyto.2009.11.017

    Article  CAS  PubMed  Google Scholar 

  44. Juarez E, Nunez C, Sada E, Ellner JJ, Schwander SK, Torres M (2010) Differential expression of toll-like receptors on human alveolar macrophages and autologous peripheral monocytes. Respir Res 11:2

    Article  PubMed  PubMed Central  Google Scholar 

  45. Waugh DJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14(21):6735–6741. doi:10.1158/1078-0432.CCR-07-4843

    Article  CAS  PubMed  Google Scholar 

  46. Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E (2006) The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25(3):387–408. doi:10.1007/s10555-006-9004-4

    Article  CAS  PubMed  Google Scholar 

  47. Chen JJ, Yao PL, Yuan A, Hong TM, Shun CT, Kuo ML, Lee YC, Yang PC (2003) Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 9(2):729–737

    CAS  PubMed  Google Scholar 

  48. Millar HJ, Nemeth JA, McCabe FL, Pikounis B, Wickstrom E (2008) Circulating human interleukin-8 as an indicator of cancer progression in a nude rat orthotopic human non-small cell lung carcinoma model. Cancer Epidemiol Biomarkers Prev 17(8):2180–2187. doi:10.1158/1055-9965.EPI-07-2915

    Article  CAS  PubMed  Google Scholar 

  49. Culig Z (2011) Cytokine disbalance in common human cancers. Biochim Biophys Acta 1813(2):308–314. doi:10.1016/j.bbamcr.2010.12.010

    Article  CAS  PubMed  Google Scholar 

  50. Albulescu R, Codrici E, Popescu ID, Mihai S, Necula LG, Petrescu D, Teodoru M, Tanase CP (2013) Cytokine patterns in brain tumour progression. Mediat Inflamm 2013:7. doi:10.1155/2013/979748

    Article  Google Scholar 

  51. Pellegrini P, Contasta I, Del Beato T, Ciccone F, Berghella AM (2011) Gender-specific cytokine pathways, targets, and biomarkers for the switch from health to adenoma and colorectal cancer. Clin Dev Immunol 819724. doi:10.1155/2011/819724

  52. Schuurs AH, Verheul HA (1990) Effects of gender and sex steroids on the immune response. J Steroid Biochem 35(2):157–172

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the Institute for Breathing and Sleep project Grant and the School of Medical Sciences, RMIT University Grant Scheme.

Ethical Approval

Human Ethics approval was received from RMIT University Human Research Ethics Committee ASEHAPP 15-13 and the informed consent of all participants was obtained.

Author information

Authors and Affiliations

  1. Cancer & Tissue Repair Laboratory, School of Medical Sciences, RMIT University, P.O. Box 71, Bundoora, Victoria, Australia, 3083

    S. A. Almatroodi, I. A. Darby & D. S. Pouniotis

  2. Institute for Breathing & Sleep, Austin Health, Heidelberg, Victoria, 3084, Australia

    C. F. McDonald

  3. Applied Medical Sciences College, Qassim University, Buraidah, Saudi Arabia

    S. A. Almatroodi

Authors
  1. S. A. Almatroodi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. F. McDonald
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. A. Darby
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. S. Pouniotis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. A. Almatroodi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Almatroodi, S.A., McDonald, C.F., Darby, I.A. et al. Characterization of M1/M2 Tumour-Associated Macrophages (TAMs) and Th1/Th2 Cytokine Profiles in Patients with NSCLC. Cancer Microenvironment 9, 1–11 (2016). https://doi.org/10.1007/s12307-015-0174-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12307-015-0174-x

Keywords

Search

Navigation